Bioactive natural products for chemoprevention and treatment of castration-resistant prostate cancer

Seminars in Cancer Biology

Volumn 40_41, Issue , 2016, Pages 160-169

  Kallifatidis, Georgios ^a   Hoy, James J ^a   Lokeshwar, Bal L ^a,b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Androgen receptor inhibitors; Anticancer natural products; Cancer prevention; Protein stability; Regulation

Indexed keywords

3,3' DIINDOLYLMETHANE; ABIRATERONE ACETATE; ALPHA TOCOPHEROL; ANDROGEN; ANDROGEN RECEPTOR; BETULIC ACID; CABAZITAXEL; CAPSAICIN; CURCUMIN; DOCETAXEL; ELLAGIC ACID; ELLAGITANNIN; EMODIN; ENZALUTAMIDE; EPICATECHIN GALLATE; EPIGALLOCATECHIN GALLATE; FINASTERIDE; GENISTEIN; ISOFLAVONE DERIVATIVE; LYCOPENE; NATURAL PRODUCT; PLACEBO; POLYPHENOL; SELENOMETHIONINE; SILIBININ; SIPULEUCEL T; STEROID 5ALPHA REDUCTASE INHIBITOR; SULFORAPHANE; UNINDEXED DRUG; VITAMIN D; ANTINEOPLASTIC AGENT; PLANT EXTRACT;

ANDROGEN DEPRIVATION THERAPY; ANDROGEN SYNTHESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CANCER GROWTH; CANCER INCIDENCE; CANCER INHIBITION; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CHEMOPROPHYLAXIS; CONVULSION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; GASTROINTESTINAL TOXICITY; HUMAN; METASTASIS INHIBITION; ORCHIECTOMY; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SPASTICITY; TRANSACTIVATION; UNSPECIFIED SIDE EFFECT; ANIMAL; DIET; DRUG SCREENING; MALE;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DIET; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MALE; PLANT EXTRACTS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84992202564     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2016.06.003     Document Type: Review

References (114)

1. [1] Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics. CA Cancer J. Clin. 66:1 (2016), 7–30.
2. [2] McCarty, M.F., Hejazi, J., Rastmanesh, R., Beyond androgen deprivation: ancillary integrative strategies for targeting the androgen receptor addiction of prostate cancer. Integr. Cancer Ther. 13:5 (2014), 386–395.
3. [3] Sarkar, F.H., et al. Novel targets for prostate cancer chemoprevention. Endocr. Relat. Cancer 17:3 (2010), R195–212.
4. [4] Joshi, G., et al. Growth factors mediated cell signalling in prostate cancer progression: implications in discovery of anti-prostate cancer agents. Chem. Biol. Interact. 240 (2015), 120–133.
5. [5] Amato, R., Stepankiw, M., Gonzales, P., A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer. Cancer Chemother. Pharmacol. 71:6 (2013), 1629–1634.
6. [6] Ezzell, E.E., Chang, K.S., George, B.J., New agents in the arsenal to fight castrate-resistant prostate cancer. Curr. Oncol. Rep. 15:3 (2013), 239–248.
7. [7] Agarwal, N., et al. New agents for prostate cancer. Ann. Oncol. 25:9 (2014), 1700–1709.
8. [8] Violette, P.D., Saad, F., Chemoprevention of prostate cancer: myths and realities. J. Am. Board Family Med. 25:1 (2012), 111–119.
9. [9] Grossmann, M.E., Huang, H., Tindall, D.J., Androgen receptor signaling in androgen-refractory prostate cancer. J. Natl. Cancer Inst. 93:22 (2001), 1687–1697.
10. [10] Titus, M.A., et al. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin. Cancer Res. 11:13 (2005), 4653–4657.
11. [11] Montgomery, R.B., et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 68:11 (2008), 4447–4454.
12. [12] Chang, K.H., et al. A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell 154:5 (2013), 1074–1084.
13. [13] Dillard, P.R., Lin, M.F., Khan, S.A., Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol. Cell. Endocrinol. 295:1–2 (2008), 115–120.
14. [14] Edwards, J., et al. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br. J. Cancer 89:3 (2003), 552–556.
15. [15] Levina, E., et al. Identification of novel genes that regulate androgen receptor signaling and growth of androgen-deprived prostate cancer cells. Oncotarget 6:15 (2015), 13088–13104.
16. [16] Aggarwal, S., et al. An overview on 5alpha-reductase inhibitors. Steroids 75:2 (2010), 109–153.
17. [17] Yamana, K., Labrie, F., Luu-The, V., Human type 3 5alpha-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride. Horm. Mol. Biol Clin. Investig. 2:3 (2010), 293–299.
18. [18] Thompson, I.M., Coltman, C.A. Jr., Crowley, J., Chemoprevention of prostate cancer. Prostate 33:3 (1997), 217–221.
19. [19] Thompson, I.M., Tangen, C., Goodman, P., The prostate cancer prevention trial: design, status, and promise. World J. Urol. 21:1 (2003), 28–30.
20. [20] Thompson, I.M., et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349:3 (2003), 215–224.
21. [21] Thompson, I.M. Jr., et al. Long-term survival of participants in the prostate cancer prevention trial. N. Engl. J. Med. 369:7 (2013), 603–610.
22. [22] Chau, C.H., et al. Finasteride concentrations and prostate cancer risk: results from the prostate cancer prevention trial. PLoS One, 10(5), 2015, e0126672.
23. [23] Klein, E.A., et al. Vitamin E and the risk of prostate cancer: the selenium and vitamin e cancer prevention trial (SELECT). JAMA 306:14 (2011), 1549–1556.
24. [24] Schwartz, G.G., Vitamin D in blood and risk of prostate cancer: lessons from the selenium and vitamin E cancer prevention trial and the prostate cancer prevention Trial. Cancer Epidemiol. Biomarkers Prev. 23:8 (2014), 1447–1449.
25. [25] Wilt, T.J., et al. Radical prostatectomy versus observation for localized prostate cancer. N. Engl. J. Med. 367:3 (2012), 203–213.
26. [26] Mann, J., Natural products in cancer chemotherapy: past, present and future. Nat. Rev. Cancer 2:2 (2002), 143–148.
27. [27] Reddy, L., Odhav, B., Bhoola, K.D., Natural products for cancer prevention: a global perspective. Pharmacol. Ther. 99:1 (2003), 1–13.
28. [28] Horie, S., Chemoprevention of prostate cancer: soy isoflavones and curcumin. Korean J. Urol. 53:10 (2012), 665–672.
29. [29] Cimino, S., et al. Polyphenols: key issues involved in chemoprevention of prostate cancer. Oxid. Med. Cell Longev., 2012, 2012, 632959.
30. [30] Saad, F., Fizazi, K., Androgen deprivation therapy and secondary hormone therapy in the management of hormone-sensitive and castration-resistant prostate cancer. Urology 86:5 (2015), 852–861.
31. [31] Grant, P., Ramasamy, S., An update on plant derived anti-androgens. Int. J. Endocrinol. Metab. 10:2 (2012), 497–502.
32. [32] Fujita, R., et al. Anti-androgenic activities of Ganoderma lucidum. J. Ethnopharmacol. 102:1 (2005), 107–112.
33. [33] Liu, J., et al. Quantitative determination of the representative triterpenoids in the extracts of Ganoderma lucidum with different growth stages using high-performance liquid chromatography for evaluation of their 5α-reductase inhibitory properties. Food Chem. 133:3 (2012), 1034–1038.
34. [34] Siddiqui, I.A., et al. Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. FASEB J. 25:4 (2011), 1198–1207.
35. [35] Liao, S., Hiipakka, R.A., Selective inhibition of steroid 5 alpha-reductase isozymes by tea epicatechin-3-gallate and epigallocatechin-3-gallate. Biochem. Biophys. Res. Commun. 214:3 (1995), 833–838.
36. [36] Hawthorne, S., Gallagher, S., Effects of glycyrrhetinic acid and liquorice extract on cell proliferation and prostate-specific antigen secretion in LNCaP prostate cancer cells. J. Pharm. Pharmacol. 60:5 (2008), 661–666.
37. [37] Watson, P.A., Arora, V.K., Sawyers, C.L., Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat. Rev. Cancer 15:12 (2015), 701–711.
38. [38] Chen, C.D., et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10:1 (2004), 33–39.
39. [39] Tan, J., et al. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol. Endocrinol. 11:4 (1997), 450–459.
40. [40] Veldscholte, J., et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun. 173:2 (1990), 534–540.
41. [41] Bhuiyan, M.M., et al. Down-regulation of androgen receptor by 3,3’-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res. 66:20 (2006), 10064–10072.
42. [42] Li, Y., Sarkar, H., Role of BioResponse 3,3’-diindolylmethane in the treatment of human prostate cancer: clinical experience. Med. Princ. Pract. 25:suppl. (2) (2016), 11–17.
43. [43] Zhou, D.Y., et al. Curcumin analogues with high activity for inhibiting human prostate cancer cell growth and androgen receptor activation. Mol. Med. Rep. 10:3 (2014), 1315–1322.
44. [44] Kuttan, R., et al. Potential anticancer activity of turmeric (Curcuma longa). Cancer Lett. 29:2 (1985), 197–202.
45. [45] Huang, M.T., et al. Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res. 54:22 (1994), 5841–5847.
46. [46] Huang, M.T., et al. Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res. 48:21 (1988), 5941–5946.
47. [47] Huang, M.T., et al. Inhibitory effects of curcumin on tumor initiation by benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene. Carcinogenesis 13:11 (1992), 2183–2186.
48. [48] Ohtsu, H., et al. Antitumor agents. 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents. J. Med. Chem. 45:23 (2002), 5037–5042.
49. [49] Wei, X., et al. Synthesis and evaluation of curcumin-related compounds for anticancer activity. Eur. J. Med. Chem. 53 (2012), 235–245.
50. [50] Culig, Z., et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 54:20 (1994), 5474–5478.
51. [51] Yeh, S., et al. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl. Acad. Sci. U. S. A. 96:10 (1999), 5458–5463.
52. [52] Guo, Z., et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 10:4 (2006), 309–319.
53. [53] Mellinghoff, I.K., et al. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6:5 (2004), 517–527.
54. [54] Gregory, C.W., et al. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin. Cancer Res. 11:5 (2005), 1704–1712.
55. [55] Mahajan, N.P., et al. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc. Natl. Acad. Sci. U. S. A. 104:20 (2007), 8438–8443.
56. [56] Andersen, R.J., et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 17:6 (2010), 535–546.
57. [57] Myung, J.K., et al. An androgen receptor N-terminal domain antagonist for treating prostate cancer. J. Clin. Investig. 123:7 (2013), 2948–2960.
58. [58] Meimetis, L.G., et al. Niphatenones, glycerol ethers from the sponge Niphates digitalis block androgen receptor transcriptional activity in prostate cancer cells: structure elucidation, synthesis, and biological activity. J. Med. Chem. 55:1 (2012), 503–514.
59. [59] Sadar, M.D., et al. Sintokamides A to E, chlorinated peptides from the sponge Dysidea sp. that inhibit transactivation of the N-terminus of the androgen receptor in prostate cancer cells. Org. Lett. 10:21 (2008), 4947–4950.
60. [60] Zhang, L., et al. NF-kappaB regulates androgen receptor expression and prostate cancer growth. Am. J. Pathol. 175:2 (2009), 489–499.
61. [61] Nakamura, K., et al. Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines. Int. J. Oncol. 21:4 (2002), 825–830.
62. [62] Araki, S., et al. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res. 67:14 (2007), 6854–6862.
63. [63] Hoshino, K., et al. Regulation of androgen receptor expression through angiotensin II type 1 receptor in prostate cancer cells. Prostate 71:9 (2011), 964–975.
64. [64] Lee, J.W., Kim, G.Y., Kim, J.H., Androgen receptor is up-regulated by a BLT2-linked pathway to contribute to prostate cancer progression. Biochem. Biophys. Res. Commun. 420:2 (2012), 428–433.
65. [65] Choi, K.C., et al. Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation. Cancer Res. 69:2 (2009), 583–592.
66. [66] Sainz, R.M., et al. Critical role of glutathione in melatonin enhancement of tumor necrosis factor and ionizing radiation-induced apoptosis in prostate cancer cells in vitro. J. Pineal Res. 45:3 (2008), 258–270.
67. [67] Rettig, M.B., et al. Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-kappaB-dependent mechanism. Mol. Cancer Ther. 7:9 (2008), 2662–2671.
68. [68] Dong, Y., et al. Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. Cancer Res. 63:1 (2003), 52–59.
69. [69] Zhao, H., et al. Diverse effects of methylseleninic acid on the transcriptional program of human prostate cancer cells. Mol. Biol. Cell 15:2 (2004), 506–519.
70. [70] Christensen, M.J., et al. High selenium reduces NF-kappaB-regulated gene expression in uninduced human prostate cancer cells. Nutr. Cancer 58:2 (2007), 197–204.
71. [71] Li, Y., et al. Regulation of Akt/FOXO3a/GSK-3beta/AR signaling network by isoflavone in prostate cancer cells. J. Biol. Chem. 283:41 (2008), 27707–27716.
72. [72] Mahmoud, A.M., et al. Differential effects of genistein on prostate cancer cells depend on mutational status of the androgen receptor. PLoS One, 8(10), 2013, e78479.
73. [73] Lazarevic, B., Karlsen, S.J., Saatcioglu, F., Genistein differentially modulates androgen-responsive gene expression and activates JNK in LNCaP cells. Oncol. Rep. 19:5 (2008), 1231–1235.
74. [74] Gao, S., Liu, G.Z., Wang, Z., Modulation of androgen receptor-dependent transcription by resveratrol and genistein in prostate cancer cells. Prostate 59:2 (2004), 214–225.
75. [75] Maggiolini, M., et al. The mutant androgen receptor T877A mediates the proliferative but not the cytotoxic dose-dependent effects of genistein and quercetin on human LNCaP prostate cancer cells. Mol. Pharmacol. 62:5 (2002), 1027–1035.
76. [76] Mahmoud, A.M., Yang, W., Bosland, M.C., Soy isoflavones and prostate cancer: a review of molecular mechanisms. J. Steroid Biochem. Mol. Biol. 140 (2014), 116–132.
77. [77] Shamaladevi, N., et al. Ericifolin: a novel antitumor compound from allspice that silences androgen receptor in prostate cancer. Carcinogenesis 34:8 (2013), 1822–1832.
78. [78] Mori, A., et al. Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells. Cancer Res. 66:6 (2006), 3222–3229.
79. [79] Malagarie-Cazenave, S., et al. Capsaicin, a component of red peppers, induces expression of androgen receptor via PI3K and MAPK pathways in prostate LNCaP cells. FEBS Lett. 583:1 (2009), 141–147.
80. [80] Diaz-Laviada, I., Effect of capsaicin on prostate cancer cells. Future Oncol. 6:10 (2010), 1545–1550.
81. [81] Friedrichs, W., et al. Omega-3 fatty acid inhibition of prostate cancer progression to hormone independence is associated with suppression of mTOR signaling and androgen receptor expression. Nutr. Cancer 63:5 (2011), 771–777.
82. [82] Wang, S., et al. Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer. Carcinogenesis 33:2 (2012), 404–412.
83. [83] Solit, D.B., Scher, H.I., Rosen, N., Hsp90 as a therapeutic target in prostate cancer. Semin. Oncol. 30:5 (2003), 709–716.
84. [84] Li, J., et al. Berberine suppresses androgen receptor signaling in prostate cancer. Mol. Cancer Ther. 10:8 (2011), 1346–1356.
85. [85] Ai, J., et al. HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer. Mol. Endocrinol. 23:12 (2009), 1963–1972.
86. [86] Kovacs, J.J., et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 18:5 (2005), 601–607.
87. [87] Davis, J.N., Kucuk, O., Sarkar, F.H., Expression of prostate-specific antigen is transcriptionally regulated by genistein in prostate cancer cells. Mol. Carcinog. 34:2 (2002), 91–101.
88. [88] Basak, S., et al. Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function. Mol. Cancer Ther. 7:10 (2008), 3195–3202.
89. [89] Gibbs, A., et al. Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. Proc. Natl. Acad. Sci. U. S. A. 106:39 (2009), 16663–16668.
90. [90] Fulda, S., Betulinic Acid for cancer treatment and prevention. Int. J. Mol. Sci. 9:6 (2008), 1096–1107.
91. [91] Reiner, T.et al., Betulinic acid selectively increases protein degradation and enhances prostate cancer-specific apoptosis: possible role for inhibition of deubiquitinase activity. PLoS One, 8(2), 2013, e56234.
92. [92] Reyes-Turcu, F.E., Ventii, K.H., Wilkinson, K.D., Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu. Rev. Biochem 78 (2009), 363–397.
93. [93] Hussain, S., Zhang, Y., Galardy, P.J., DUBs and cancer: the role of deubiquitinating enzymes as oncogenes, non-oncogenes and tumor suppressors. ABBV Cell Cycle 8:11 (2009), 1688–1697.
94. [94] Sacco, J.J., et al. Emerging roles of deubiquitinases in cancer-associated pathways. IUBMB Life 62:2 (2010), 140–157.
95. [95] Cha, T.L., et al. Emodin modulates epigenetic modifications and suppresses bladder carcinoma cell growth. Mol. Carcinog. 54:3 (2015), 167–177.
96. [96] Cha, T.L., et al. Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth. Cancer Res. 65:6 (2005), 2287–2295.
97. [97] Fu, M.F., et al. p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J. Biol. Chem. 275:27 (2000), 20853–20860.
98. [98] Coffey, K., Robson, C.N., Regulation of the androgen receptor by post-translational modifications. J. Endocrinol. 215:2 (2012), 221–237.
99. [99] Wang, Z.H., et al. Inactivation of androgen-induced regulator ARD1 inhibits androgen receptor acetylation and prostate tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 109:8 (2012), 3053–3058.
100. [100] Lee, Y.H., et al. EGCG suppresses prostate cancer cell growth modulating acetylation of androgen receptor by anti-histone acetyltransferase activity. Int. J. Mol. Med. 30:1 (2012), 69–74.
101. [101] Roell, D., Baniahmad, A., The natural compounds atraric acid and N-butylbenzene-sulfonamide as antagonists of the human androgen receptor and inhibitors of prostate cancer cell growth. Mol. Cell. Endocrinol. 332:1–2 (2011), 1–8.
102. [102] Papaioannou, M., et al. The natural compound atraric acid is an antagonist of the human androgen receptor inhibiting cellular invasiveness and prostate cancer cell growth. J. Cell. Mol. Med. 13:8B (2009), 2210–2223.
103. [103] Shenouda, N.S., et al. Phytosterol Pygeum africanum regulates prostate cancer in vitro and in vivo. Endocrine 31:1 (2007), 72–81.
104. [104] Schleich, S., et al. Activity-guided isolation of an antiandrogenic compound of Pygeum africanum. Planta Med. 72:6 (2006), 547–551.
105. [105] Schleich, S., et al. Extracts from Pygeum africanum and other ethnobotanical species with antiandrogenic activity. Planta Med. 72:9 (2006), 807–813.
106. [106] Papaioannou, M., et al. NBBS isolated from Pygeum africanum bark exhibits androgen antagonistic activity, inhibits AR nuclear translocation and prostate cancer cell growth. Invest. New Drugs 28:6 (2010), 729–743.
107. [107] Anand, P., et al. Bioavailability of curcumin: problems and promises. Mol. Pharm. 4:6 (2007), 807–818.
108. [108] Meyskens, F.L. Jr., et al. Cancer prevention: obstacles, challenges and the road ahead. J. Natl. Cancer Inst., 108(2), 2016.
109. [109] Shaikh, J., et al. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur. J. Pharm. Sci. 37:3–4 (2009), 223–230.
110. [110] Siviero, A., et al. Curcumin, a golden spicewith a low bioavailability. J. Herbal Med. 5:2 (2015), 57–70.
111. NG) in patients with prostate cancer who are undergoing prostatectomy. Eur. J. Cancer Prev. 25:4 (2016), 312–320.
112. [112] Lallous, N., et al. Targeting alternative sites on the androgen receptor to treat castration-resistant prostate cancer. Int. J. Mol. Sci. 14:6 (2013), 12496–12519.
113. [113] Caboni, L., Lloyd, D.G., Beyond the ligand-binding pocket: targeting alternate sites in nuclear receptors. Med. Res. Rev. 33:5 (2013), 1081–1118.
114. [114] Amirian, E.S., et al. Potential role of gastrointestinal microbiota composition in prostate cancer risk. Infect. Agent Cancer, 8(1), 2013, 42.